How does xcube.bio work?
“Build together” relies on each partner strengths to serve a temporary purpose: settling in a new geography
An optimal sharing of value with similar risk profile as a Licensing agreement
An entity with full oversight and mid-term control
Optionality protected for innovator: entity buy back, carry-on, switch to licensing, exit.
A complete incubation process to switch progressively toward commercial-stage
Xcube.bio delivers full scale commercial building program through a mix of hands-on decision support, co-investment and operational solutions allowing biopharma innovators to achieve maximum commercial potential.
Clarify the commercial ambition. Understand the patient journey, formalize the anticipated commercial features of the asset and design the go-to-market model to succeed in markets.
Xcube.bio brings hands-on expertise to design the commercial success
Prepare for the future. Make the right early decision to upgrade the asset from “approvable” to “marketable”. Execute the initial engagement with local stakeholders, potential partners and suppliers. Optimize the commercial potential and validate the investment needs with field input.
Xcube.bio delivers day-to-day management, decision support and targeted expertise as a virtual liaison office
Time to initiate action. Upgrade engagement with market stakeholders, solidify partner and supplier relationships, finalize plans for commercial processes and systems, and scout for talents.
Xcube.bio undertakes the initial tasks until Marketing Authorization (MA) as a Virtual prelaunch squad fully syncs with innovator
The rubber hits the road. Commercial operational entities are created, systems and distribution are deployed, and key recruits are onboarded.
Xcube.bio ensures legal, organizational, and people readiness as a co-invested partner
Deliver the launch. Progressively deploy across the target territories, ramp up customer-facing teams, and deliver outcomes for patients.
The commercial entity executes the launch plan under the scientific supervision of the Innovator and operational advisory of Xcube.bio.
Time to exit. The mature commercial entity is fully owned by the innovator. Systems and processes are integrated to innovators. The commercial entity continue its growth journey.
Xcube.bio is hands-off. It is all to the innovator now standing as a full scale commercial-stage biotech